{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:35:42Z","timestamp":1792136142643,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00228-025-03918-3","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T05:45:42Z","timestamp":1757396742000},"page":"1833-1839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of ultrafiltration conditions on the unbound fraction of phenytoin and valproic acid"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-4682","authenticated-orcid":false,"given":"Pjotr P.","family":"Temme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-887X","authenticated-orcid":false,"given":"Matthijs","family":"van Luin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-6420","authenticated-orcid":false,"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-9892","authenticated-orcid":false,"given":"Nynke G. L.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2531-3623","authenticated-orcid":false,"given":"Mirte M.","family":"Malingr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"7","key":"3918_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD et al (2008) Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 49(7):1239\u20131276. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x","journal-title":"Epilepsia"},{"issue":"1","key":"3918_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/FTD.0b013e3181c13a30","volume":"32","author":"J Haymond","year":"2010","unstructured":"Haymond J, Ensom MHH (2010) Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? Ther Drug Monit 32(1):19\u201329. https:\/\/doi.org\/10.1097\/FTD.0b013e3181c13a30","journal-title":"Ther Drug Monit"},{"issue":"5","key":"3918_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ (2018) Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit 40(5):526\u2013548. https:\/\/doi.org\/10.1097\/FTD.0000000000000546","journal-title":"Ther Drug Monit"},{"issue":"7","key":"3918_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/epi.13802","volume":"58","author":"PN Patsalos","year":"2017","unstructured":"Patsalos PN, Zugman M, Lake C, James A, Ratnaraj N, Sander JW (2017) Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia 58(7):1234\u20131243. https:\/\/doi.org\/10.1111\/epi.13802","journal-title":"Epilepsia"},{"issue":"4","key":"3918_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1254\/jphs.FPE04007X","volume":"97","author":"J Hermida","year":"2005","unstructured":"Hermida J, Tutor JC (2005) A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients. J Pharmacol Sci 97(4):489\u2013493. https:\/\/doi.org\/10.1254\/jphs.FPE04007X","journal-title":"J Pharmacol Sci"},{"issue":"10","key":"3918_CR6","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/bcp.14053","volume":"85","author":"R Ter Heine","year":"2019","unstructured":"Ter Heine R, Kane SP, Huitema ADR, Krasowski MD, van Maarseveen EM (2019) Nonlinear protein binding of phenytoin in clinical practice: development and validation of a mechanistic prediction model. Br J Clin Pharmacol 85(10):2360\u20132368. https:\/\/doi.org\/10.1111\/bcp.14053","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"3918_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000987","volume":"5","author":"JT Liu","year":"2023","unstructured":"Liu JT, Brown CS, Mara KC et al (2023) Derivation and validation of a new equation for estimating free valproate concentration in critically ill adult patients. Crit Care Explor 5(10):e0987. https:\/\/doi.org\/10.1097\/CCE.0000000000000987","journal-title":"Crit Care Explor"},{"issue":"1","key":"3918_CR8","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1212\/WNL.0000000000011000","volume":"96","author":"U Fisch","year":"2021","unstructured":"Fisch U, Baumann SM, Semmlack S, Marsch S, Ruegg S, Sutter R (2021) Accuracy of calculated free valproate levels in adult patients with status epilepticus. Neurology 96(1):e102\u2013e110. https:\/\/doi.org\/10.1212\/WNL.0000000000011000","journal-title":"Neurology"},{"issue":"4","key":"3918_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3349\/ymj.2009.50.4.517","volume":"50","author":"J Hong","year":"2009","unstructured":"Hong J, Choi Y, Kim W (2009) Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J 50(4):517\u2013520. https:\/\/doi.org\/10.3349\/ymj.2009.50.4.517","journal-title":"Yonsei Med J"},{"issue":"24","key":"3918_CR10","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.4155\/bio.13.274","volume":"5","author":"LB Nilsson","year":"2013","unstructured":"Nilsson LB (2013) The bioanalytical challenge of determining unbound concentration and protein binding for drugs. Bioanalysis 5(24):3033\u20133050. https:\/\/doi.org\/10.4155\/bio.13.274","journal-title":"Bioanalysis"},{"issue":"5","key":"3918_CR11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/jac\/dkae092","volume":"79","author":"NGL Jager","year":"2024","unstructured":"Jager NGL, Van Ewijk-BenekenKolmer E, Aarnoutse R, Te Brake LHM (2024) Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example. J Antimicrob Chemother 79(5):1187\u20131190. https:\/\/doi.org\/10.1093\/jac\/dkae092","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3918_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/FTD.0000000000000351","volume":"38","author":"NA Stienstra","year":"2016","unstructured":"Stienstra NA, Sikma MA, van Dapperen AL, de Lange DW, van Maarseveen EM (2016) Development of a simple and rapid method to measure the free fraction of tacrolimus in plasma using ultrafiltration and LC-MS\/MS. Ther Drug Monit 38(6):722\u2013727. https:\/\/doi.org\/10.1097\/FTD.0000000000000351","journal-title":"Ther Drug Monit"},{"issue":"5","key":"3918_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/00007691-199009000-00010","volume":"12","author":"N Ratnaraj","year":"1990","unstructured":"Ratnaraj N, Goldberg VD, Hjelm M (1990) Temperature effects on the estimation of free levels of phenytoin carbamazepine and phenobarbitone. Ther Drug Monit 12(5):465\u2013472. https:\/\/doi.org\/10.1097\/00007691-199009000-00010","journal-title":"Ther Drug Monit"},{"issue":"3","key":"3918_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0939-6411(99)00008-9","volume":"47","author":"H Kodama","year":"1999","unstructured":"Kodama H, Kodama Y, Shinozawa S, Kanemaru R, Todaka K, Mitsuyama Y (1999) Temperature effect on serum protein binding kinetics of phenytoin in monotherapy patients with epilepsy. Eur J Pharm Biopharm 47(3):295\u2013298. https:\/\/doi.org\/10.1016\/S0939-6411(99)00008-9","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"3918_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00007691-200502000-00014","volume":"27","author":"PH Hinderling","year":"2005","unstructured":"Hinderling PH, Hartmann D (2005) The pH dependency of the binding of drugs to plasma proteins in man. Ther Drug Monit 27(1):71\u201385. https:\/\/doi.org\/10.1097\/00007691-200502000-00014","journal-title":"Ther Drug Monit"},{"issue":"2","key":"3918_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2125.1982.tb01981.x","volume":"14","author":"GM Peterson","year":"1982","unstructured":"Peterson GM, McLean S, Aldous S, Von Witt RJ, Millingen KS (1982) Plasma protein binding of phenytoin in 100 epileptic patients. Br J Clin Pharmacol 14(2):298\u2013300.","journal-title":"Br J Clin Pharmacol"},{"key":"3918_CR17","unstructured":"Werkgroep TDM, Toxicologie en Famacogenetica van de Nederlandse Vereniging van Ziekenhuisapothekers. TDM monografie valproinezuur. https:\/\/tdm-monografie.org\/valproinezuur\/. Accessed 11 Apr 2025"},{"issue":"9","key":"3918_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238201","volume":"15","author":"Y Tseng","year":"2020","unstructured":"Tseng Y, Huang S, Kuo C, Wang C, Wang K, Wu C (2020) Safety range of free valproic acid serum concentration in adult patients. PLoS ONE 15(9):e0238201. https:\/\/doi.org\/10.1371\/journal.pone.0238201","journal-title":"PLoS ONE"},{"issue":"1","key":"3918_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/JCP.0b013e318203b405","volume":"31","author":"T Sriboonruang","year":"2011","unstructured":"Sriboonruang T, Panomvana D, Chamchitchun S, Silpakit O (2011) The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. J Clin Psychopharmacol 31(1):115\u2013119. https:\/\/doi.org\/10.1097\/JCP.0b013e318203b405","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"3918_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/FTD.000000000","volume":"39","author":"E Wallenburg","year":"2017","unstructured":"Wallenburg E, Klok B, de Jong K et al (2017) Monitoring protein-unbound valproic acid serum concentrations in clinical practice. Ther Drug Monit 39(3):269\u2013272. https:\/\/doi.org\/10.1097\/FTD.000000000","journal-title":"Ther Drug Monit"},{"key":"3918_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69102-y","volume":"10","author":"D Metsu","year":"2020","unstructured":"Metsu D, Lanot T, Fraissinet F et al (2020) Comparing ultrafiltration and equilibrium dialysis to measure unbound plasma dolutegravir concentrations based on a design of experiment approach. Sci Rep 10:12265. https:\/\/doi.org\/10.1038\/s41598-020-69102-y","journal-title":"Sci Rep"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03918-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:43:49Z","timestamp":1764909829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03918-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3918"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03918-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient samples collected for routine TDM of PHT or VPA were used of patients that provided general consent for the use of their data for research purposes upon admission to the hospital. Patient samples and data were processed anonymously.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval"}},{"value":"The authors declare no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}]}}